ClinicalTrials.gg
CompletedNCT00685529Updated Feb 22, 2012

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Racemic formoterol and Arformoterol tartrate inhalation solution in COPD, sponsored by Sumitomo Pharma America, Inc.. Completed at 6 sites in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Sumitomo Pharma Co., Ltd..

Enrollment
23rd of 24
24 · median 225
Started
2005
with 2 others
Phase 2
7 of 24
none open now
Registered
9th of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 23rd largest by enrollment, is one of 3 that started in 2005, is one of 7 in phase 2, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. as a file.
02

Study summary

The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).

Read the detailed description

This is an open label, randomized, multiple dose, 3-way crossover, multicenter, inpatient and outpatient study to compare the pharmacokinetic (PK) profile of arformoterol tartrate inhalation solution and Foradil® in male and female subjects with mild to moderate COPD. Up to 36 subjects (with a minimum 40% of each gender) were to be randomized to ensure that at minimum 24 subjects completed the study. The study included 3 dose periods and 3 washout periods. Subjects received 3 different treatments in random order for 13 consecutive days and a single dose on the morning of the 14th day. Subjects will be randomly assigned to 1 of the 6 possible treatment sequences. During each dose period, subjects received medication via nebulization or DPI twice daily for 13 consecutive days and a single dose on the morning of the 14th day. There was be a 10 day washout period between each treatment. Subject participation was be approximately 13 weeks and included a screening visit and 7 study visits. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Arformoterol
  • formoterol
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects must be at least 35 years old at the time of consent.
  • Female subjects less than or equal to 65 years old must have a negative serum pregnancy test at Visit 1 and a urine pregnancy test at Visit 2, confirmed negative prior to randomization. Subjects of must be using an acceptable method of .
  • Subjects must have a documented primary clinical diagnosis of non-asthmatic
  • Subjects must have a ≥ 15 pack-year smoking history
  • Subjects must be in general good health.
  • Subjects must have a minimum blood pressure of 105/60 mmHg and a minimum resting pulse of 50 bpm at Screening Visit 1.
  • Subjects must have a (BMI) of at least 16 kg/m2 but no more than 30 kg/m2. (BMI is defined as the subject's weight in kilograms divided by the square of the subject's height in meters.)
  • Subjects must be willing to remain in the residential facility for 3 separate 24 hour visits and 3 separate 36-hour visits.
  • Subjects must agree to refrain from strenuous activities, as defined by the Principal Investigator, throughout the study, from the screening visit until after the end of study/early termination visit.

Exclusion criteria

Exclusion Criteria:

  • Subject has had a febrile illness within 72 hours (3 days) before Screening.
  • Subject has any unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, gastrointestinal, hepatic, or renal systems, which, in the opinion of the investigator, may affect the safety of the subject.
  • Subject has a history of or currently has malignancy other than non melanomatous skin cancer. Subjects who have been cancer-free for 5 years or more may be enrolled.
  • Subjects with a chest x-ray that suggests a diagnosis other than (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions) and taken within 6 months prior to study start. If there is no chest x-ray taken within 6 months prior to study start, or if recent results are unavailable for review, a chest x-ray must be performed.
  • Subjects with a history of asthma, with the exception of asthma diagnosed in childhood.
  • Subject tests positive at screening for surface antigen or antibody, or the subject has a history of a positive result.
  • Subject is known to be seropositive for (HIV).
  • Female subject is pregnant or lactating.
  • Female subject who (a) is of and not using or is using hormonal contraception, or (b) is and is taking any form of hormone replacement therapy.
  • Subject has a disorder or history of a condition that may interfere with drug absorption, distribution, metabolism, or excretion (e.g., malabsorption, gastrointestinal surgery).
  • Subject has participated in any study within 30 days prior to screening or is currently participating in another clinical trial.
  • Subject is a staff member or relative of a staff member.
  • Subject has a positive urine alcohol test during screening. Subjects with a known history of alcohol use may be enrolled in the study if the subject's alcohol use is not indicative of abuse. Abuse is defined as current consumption of more than three alcoholic beverages per day.
  • Subject has a history or suspected history of abuse of a barbiturate, amphetamine, or narcotic and/or has a positive screening result for any of these substances at study start.
  • Subject has a history of allergic reaction to the study medication or any components of the study medications.
  • Subject has received oral anticoagulant therapy within 90 days before Screening.
  • Subject has had significant blood loss (>500 cc) or donated blood within 60 days preceding screening or plans to donate blood during or within 60 days after completing the study.
  • Subject has donated plasma within 72 hours prior to the first dose of study drug.
  • Subject has had an acute illness within 10 days of Day 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    A

    12 µg of racemic formoterol fumarate BID

    Drug: Racemic formoterol

  • Experimental
    B

    15 µg of nebulized arformoterol tartrate inhalation solution BID

    Drug: Arformoterol tartrate inhalation solution

  • Active comparator
    C

    24 µg of racemic formoterol fumarate BID

    Drug: Racemic formoterol

Interventions

  • 12 µg of racemic formoterol fumarate BID

    Also known as: Foradil®, Aerolizer

  • DrugArformoterol tartrate inhalation solution

    15 µg of nebulized arformoterol tartrate inhalation solution BID

    Also known as: Brovana, (R,R)-formoterol

  • 24 µg of racemic formoterol fumarate BID

    Also known as: Foradil®, Aerolizer

06

What researchers measure

Primary outcomes

  1. The primary endpoint for this study is exposure to (R,R)-formoterol, measured by the PK parameters AUC(0-τ) and Cmax

    Time frame: Treatment/Washout 1: Days 1, 12-18; T/W 2: 24, 35-40; T/W 3: 47, 58-64, EOT: 70

Secondary outcomes

  1. Additional PK parameters of (R,R)-formoterol include tmax, t ½, and AUC(0-∞)

    Time frame: Treatment/Washout 1: Days 1, 12-18; T/W 2: 24, 35-40; T/W 3: 47, 58-64, EOT: 70

  2. Accumulation ratios for (R,R)-formoterol as measured by RCmax and RAUC(0-τ)

    Time frame: Treatment/Washout 1: Days 1, 12-18; T/W 2: 24, 35-40; T/W 3: 47, 58-64, EOT: 70

  3. PK parameters for (S,S)-formoterol following racemic formoterol administration are AUC(0-τ), Cmax, tmax, t ½, and AUC(0-∞)

    Time frame: Treatment/Washout 1: Days 1, 12-18; T/W 2: 24, 35-40; T/W 3: 47, 58-64, EOT: 70

  4. Accumulation ratios for (S,S)-formoterol as measured by RCmax and RAUC(0-τ)

    Time frame: Days 1, 12, 13, 14, 15, 16, 17,18

  5. FEV1 and % predicted FEV1

    Time frame: Treatment/Washout 1: Days 1, 14-15; TW2: 24, 37-38; TW3: 47, 60-61

07

Study locations

6 sites
  • Long Beach, California, United States
  • Fort Lauderdale, Florida, United States
  • Raleigh, North Carolina, United States
  • Simpsonville, South Carolina, United States
  • Spartanburg, South Carolina, United States
  • Spokane, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2008
First posted
May 28, 2008
Start
Apr 2005
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00685529
Responsible party
Sponsor
First posted
May 28, 2008
Start date
Apr 2005
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Feb 22, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion